Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 3/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GALK1 | P51570 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17978610 | 0.76 | DDX3X (1.00) | DDX3XTRPV1 | |
| SCHEMBL19403500 | 0.74 | DDX3X (0.64) | DDX3XTRPV1KDM4EMAPTGALK1 | |
| SCHEMBL13151501 | 0.72 | TRPV1 (0.73) | TRPV1KDM4EMAPT | |
| SCHEMBL29099860 | 0.72 | TRPV1 (0.66) | DDX3XTRPV1KDM4EMAPTGALK1 | |
| SCHEMBL5660097 | 0.72 | TRPV1 (0.71) | TRPV1 | |
| SCHEMBL29099838 | 0.72 | TRPV1 (0.69) | DDX3XTRPV1KDM4EMAPTGALK1 | |
| SCHEMBL17978487 | 0.72 | DDX3X (0.63) | DDX3XTRPV1KDM4EMAPTATM | |
| SCHEMBL19784939 | 0.71 | DDX3X (0.65) | DDX3XTRPV1KDM4EMAPTLMNA | |
| SCHEMBL5657517 | 0.71 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL30544193 | 0.71 | TRPV1 (0.71) | TRPV1KDM4EMAPTGALK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | DDX3X 1/4885TRPV1 4331/4885KDM4E 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.